Charles Elliott Sigal Net Worth & Insider Trades
Charles Elliott Sigal - Director, Adaptimmune Therapeutics Plc
What is Charles Elliott Sigal's Net Worth?
The current estimated net worth of Adaptimmune Therapeutics Plc's Director, Charles Elliott Sigal, is estimated to be about $466.65K . Charles Elliott Sigal owns about 367,038 units of Adaptimmune Therapeutics Plc common stock. In the last 6 years at Adaptimmune Therapeutics Plc, Charles Elliott Sigal has sold an estimated value of $0 worth.
What is Charles Elliott Sigal's Past Insider Trading?
Charles Elliott Sigal's largest purchase order was 45,000 units , worth over $68.7K on May 18, 2016. In total, Charles Elliott Sigal has made about 9 transactions over 6 years of their time at Adaptimmune Therapeutics Plc. Charles Elliott Sigal usually trades in July, with the busiest year in 2016. The most recent transaction was a purchase order of 15,000 units , worth over $23.4K on May 19, 2016.
Charles Elliott Sigal
Date Range: All Time
Ticker
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
|---|---|---|---|---|---|---|---|
| No matching records found | |||||||
What is Charles Elliott Sigal's' Mailing Address?
- Mailing address is 32 Brearly Road Princeton NJ 08540 NJ
Adaptimmune Therapeutics Plc Executive Compensation
Name |
Year
|
Salary
|
Option Awards
|
Other Earnings Plans or Compensations
|
Other Compensation
|
Total
|
|---|---|---|---|---|---|---|
| Adrian Rawcliffe | 2020 | $574,000 | $1,715,346 | $378,840 | $33,416 | $2,701,602 |
| Adrian Rawcliffe | 2019 | $500,481 | $1,427,399 | $177,251 | $49,912 | $2,155,042 |
| Adrian Rawcliffe | 2018 | $457,011 | $730,791 | $174,807 | $54,775 | $1,417,384 |
| Gavin Wood | 2020 | $337,065 | $990,268 | $166,847 | $73,731 | $1,567,911 |
| Helen Tayton-Martin | 2020 | $454,940 | $857,661 | $225,195 | $23,531 | $1,561,327 |
| Helen Tayton-Martin | 2019 | $435,949 | $766,900 | $137,324 | $30,491 | $1,370,664 |
| Helen Tayton-Martin | 2018 | $408,308 | $730,791 | $156,178 | $22,007 | $1,317,284 |
| William Bertrand | 2020 | $443,456 | $857,661 | $219,511 | $30,485 | $1,551,113 |
| William Bertrand | 2019 | $432,640 | $766,900 | $136,282 | $35,358 | $1,371,180 |
| William Bertrand | 2018 | $416,000 | $685,114 | $159,120 | $35,070 | $1,295,304 |
| John Lunger | 2020 | $400,000 | $857,661 | $198,000 | $31,802 | $1,487,463 |
| John Lunger | 2019 | $366,867 | $435,546 | $94,542 | $35,655 | $932,610 |
| John Lunger | 2018 | $316,958 | $602,909 | $92,948 | $35,07 | $1,047,885 |
| Michael Garone | 2020 | $217,000 | - | - | - | $217,000 |
| Michael Garone | 2019 | $206,500 | - | - | - | $206,500 |
| No matching records found | ||||||
Source: https://www.sec.gov/Archives/edgar/data/1621227/000110465921047833/tm212433-2_def14a.htm
What are Adaptimmune Therapeutics Plc's Past Insider Trades?
Adaptimmune Therapeutics Plc's most recent insider trade came on January 17, 2023 by John Lunger who sold 4,440 units worth $8.25K . In the last 7 years, insiders at Adaptimmune Therapeutics Plc have sold an estimated value of $40.32M and bought an estimated value of $526.78M worth of shares. Insider trading is most common in January, with the busiest year in 2018. The most active traders at the company are Adrian Rawcliffe, Chief Executive Officer, John Lunger, Chief Patient Supply Officer, and William Charles Bertrand, Chief Operating Officer .
Adaptimmune Therapeutics PLC Insider Trades
Date Range: All Time
Insider Names
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
|---|---|---|---|---|---|---|---|
| No matching records found | |||||||